Astellas Pharma US Inc. and Medivation Inc. announced the initiation of a Phase 4 clinical trial, known as PLATO, evaluate the efficacy and safety of continued treatment with enzalutamide plus abiraterone acetate and prednisone in patients with chemotherapy-naïve metastatic prostate cancer.
Researchers studying how cancer spreads into bone have made a surprising discovery that suggests several investigational anti-cancer therapies just entering the drug-development pipeline may not have the desired effect.
In their ongoing quest to develop the latest and most effective drugs for disease treatment, pharmaceutical researchers are looking deep— as in, deep underground.
South Dakota philanthropist T. Denny Sanford has committed $100 million to create a California stem cell clinical center to speed research into new drugs and therapies.
This year marks the 30th anniversary of the discovery of the genetic mutation that leads to Huntington’s disease, which provides added meaning to the positive preclinical results for new therapeutics designed to treat the disease that were presented Monday at the Annual Meeting of the Society for Neuroscience being held this week in San Diego, Calif.
A North Carolina pharmaceutical plant will be closing, putting about 310 people out of work. Actavis PLC said Monday it will take until the middle of 2015 to close the plant in Lincoln County, which makes creams and ointments.
Sarepta Therapeutics Inc. said in an update that the U.S. Food and Drug Administration (FDA) currently considers the company's planned NDA submission and confirmatory clinical study with eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) to be "premature."
New treatments for prostate cancer, multiple sclerosis and cystic fibrosis could be developed following research being carried out into how medicinal "biologics’" can be delivered to diseased cells.
Bayer HealthCare announced that initial results from a Phase 2 study of Portola Pharmaceuticals’ andexanet alfa, an investigational Factor Xa inhibitor antidote, in healthy volunteers who were administered Bayer’s anticoagulant Xarelto have been accepted for presentation at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition.
GlaxoSmithKline today announced the phase 3 trial evaluating the efficacy of its investigational Lp-PLA2 inhibitor darapladib in adults with chronic coronary heart disease (CHD) did not meet its primary endpoint. What does this mean for the drug's future? Find out...
ImmunoGen Inc. announced that Novartis has licensed the exclusive right to use the company's antibody-drug conjugate (ADC) technology to develop anticancer therapeutics to an undisclosed target.
Israel's Teva Pharmaceuticals Industries Ltd. says it has reached an agreement with the country's tax authority to pay roughly $718 million to settle a series of claims against the drug maker.
Researchers successfully eliminated the native infection preferences of a Sindbis virus engineered to target and kill cancer cells, a milestone in the manipulation of this promising viral vector.
Shares of Zalicus tumbled to an all-time low today after the company said it is ending development of its most advanced experimental drug. The pain drug developer said drug candidate Z160 failed in two mid-stage clinical trials.